iOnctura is a clinical stage biopharmaceutical company dedicated to delivering innovative cancer treatments to patients with unmet medical need.
iOnctura is uncovering the key to unlock difficult to treat tumors burdened by stroma and immune mediated resistance. We do this by interrogating new mechanisms that disrupt the dynamic interplay at the heart of the tumor-stroma-immune interface.
iOnctura expands Advisory Board
iOnctura to present at ASCO IOA-244 showing highly promising impact on overall survival for patients with metastatic and refractory uveal melanoma
iOnctura to present at ASCO encouraging Phase Ib refractory uveal melanoma data for first semi-allosteric PI3Kδ inhibitor, IOA-244